Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TransCode Therapeutics, Inc. (RNAZ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8300+0.0400 (+2.23%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0900
Open2.1600
Bid1.6100 x 800
Ask2.1800 x 1400
Day's Range2.0000 - 2.1600
52 Week Range1.5200 - 7.0000
Volume58,200
Avg. Volume18,555
Market Cap23.615M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

    BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins Avenue. Virtual participation will be staged simultaneously as a live feed and available on-demand. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scien

  • GlobeNewswire

    TransCode Therapeutics Acquires Option for Radiotheranostic Technology

    BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCo

  • GlobeNewswire

    TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress. TransCode co-founder and Chief Technology Officer, Dr. Zdravka Medarova, indicated, “We believe we remain on track to submit an exploratory Investigational New Drug Application (eIND) this year to test our lead therapeutic candi

Advertisement
Advertisement